Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.
about
Autonomic neuropathy in diabetes mellitusSoluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus.Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population.Soluble Urokinase Receptor Levels Are Correlated with Focal Segmental Glomerulosclerosis Lesions in IgA Nephropathy: A Cohort Study from China.Soluble Urokinase Receptor and Chronic Kidney Disease.Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitusDiabetes mellitus in the transplanted kidney.Elevated Soluble Urokinase Plasminogen Activator Receptor and Proenkephalin Serum Levels Predict the Development of Acute Kidney Injury after Cardiac Surgery.Physiology and pathophysiology of the plasminogen system in the kidney.Soluble urokinase plasminogen activator receptor and hypertension among black South Africans after 5 years.Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies.Cardiac autonomic neuropathy in patients with diabetes mellitus: current perspectives.Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study.Serum suPAR and syndecan-4 levels predict severity of community-acquired pneumonia: a prospective, multi-centre study.Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.The intriguing role of soluble urokinase receptor in inflammatory diseases.
P2860
Q21131270-970B649C-D015-45E7-8A39-DB25BDC9A2E5Q33741426-71FE7B85-5642-4F8F-910E-089954766439Q34722262-E082AB1B-0811-4E3A-8F98-30A36AACE824Q35779133-BC16677E-0E02-45FA-8DE6-8638292E2611Q36429637-78C479CB-FFA7-4DF5-9F30-805887DA284CQ37587674-D7B7F093-2084-4A25-85FC-FB9167A4EA7EQ38249183-2FF4D1D9-6D51-4E87-907F-1D99B84AE70AQ38651999-179090D5-292E-4A80-8FB3-81C176764995Q39401678-16FFB969-57B2-4D1A-A77D-DE5BE4EDBA99Q40261498-664B7D42-BE72-4ED9-982F-3A1BEED4D2BDQ40528582-54F6FAF1-1BA9-4B29-819D-A3F3B9F9E1B0Q42627682-CC8B928E-2D84-40BF-8778-2CE665B8407DQ43086883-D2B8C7B0-BFD2-4EEF-B610-9DFC2C9F8405Q44256854-82134D74-6834-46AD-BE6F-E4169138A033Q47647911-CDAA32AE-CD41-43AC-83FE-F32A9C6AD2FEQ48331707-F38B9FB1-DB58-44DD-83CF-349A1373707EQ49124480-00E2A574-6C17-44D4-A6E8-5B586CB72784
P2860
Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Soluble urokinase plasminogen ...... patients with type 1 diabetes.
@en
Soluble urokinase plasminogen ...... patients with type 1 diabetes.
@nl
type
label
Soluble urokinase plasminogen ...... patients with type 1 diabetes.
@en
Soluble urokinase plasminogen ...... patients with type 1 diabetes.
@nl
prefLabel
Soluble urokinase plasminogen ...... patients with type 1 diabetes.
@en
Soluble urokinase plasminogen ...... patients with type 1 diabetes.
@nl
P2093
P2860
P50
P356
P1476
Soluble urokinase plasminogen ...... patients with type 1 diabetes
@en
P2093
J L Jeppesen
S Lyngbaek
S Theilade
P2860
P304
P356
10.1111/JOIM.12269
P407
P577
2014-06-23T00:00:00Z